Compare Neurocrine Biosciences Inc (NBIX) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nomura Holdings Inc — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Nomura Holdings Inc trades at $9.4 (market cap $27.46B). The key difference: Nomura Holdings Inc is the larger of the two by market cap, and Nomura Holdings Inc pays a 3.45% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NMR | |
|---|---|---|
Market Cap | $17.40B | $27.46B |
Sector | Health | Financials |
52-Week High | $180.55 | $10.04 |
52-Week Low | $123.10 | $6.39 |
Enterprise Value | $16.49B | — |
Dividend Yield | — | 3.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
